BioVie’s Parkinson drug data prompts 50% stock drop as company shifts to composite endpoint

BioVie announced phase 2 results for its experimental Parkinson’s therapy bezisterim, saying the data suggest a meaningful advance in treating the disease.

Investors reacted sharply, wiping out roughly half of the company’s market value after the firm highlighted a new composite endpoint instead of the trial’s pre‑specified primary measure.

The primary endpoint – change from baseline in MDS‑UPDRS Part III, which assesses motor function – was omitted from the press release, though a later presentation showed mixed results, with placebo outperforming the drug at low baseline platelet counts and bezisterim showing a numerical advantage at higher counts.

Analysts noted that the reliance on a secondary composite measure raises questions about the drug’s efficacy on the key motor symptoms that regulators will scrutinize, adding uncertainty to the program’s future prospects.